Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2013

Authors

Lakshmi N. Yatham, The University of British Columbia
Sidney H. Kennedy, University of Toronto
Sagar V. Parikh, University of Toronto
Ayal Schaffer, University of Toronto
Serge Beaulieu, Université McGill
Martin Alda, Dalhousie University
Claire O'Donovan, Dalhousie University
Glenda Macqueen, University of Calgary
Roger S. Mcintyre, University of Toronto
Verinder Sharma, Western UniversityFollow
Arun Ravindran, University of Toronto
L. Trevor Young, The University of British Columbia
Roumen Milev, Queen’s University
David J. Bond, The University of British Columbia
Benicio N. Frey, McMaster University
Benjamin I. Goldstein, Sunnybrook Health Sciences Centre
Beny Lafer, Universidade de São Paulo
Boris Birmaher, UPMC Western Psychiatric Hospital
Kyooseob Ha, Seoul National University
Willem A. Nolen, Universitair Medisch Centrum Groningen
Michael Berk, Deakin University

Document Type

Article

Publication Date

2-1-2013

Journal

Bipolar Disorders

Volume

15

Issue

1

First Page

1

Last Page

44

URL with Digital Object Identifier

10.1111/bdi.12025

Abstract

The Canadian Network for Mood and Anxiety Treatments published guidelines for the management of bipolar disorder in 2005, with updates in 2007 and 2009. This third update, in conjunction with the International Society for Bipolar Disorders, reviews new evidence and is designed to be used in conjunction with the previous publications.The recommendations for the management of acute mania remain largely unchanged. Lithium, valproate, and several atypical antipsychotic agents continue to be first-line treatments for acute mania. Monotherapy with asenapine, paliperidone extended release (ER), and divalproex ER, as well as adjunctive asenapine, have been added as first-line options.For the management of bipolar depression, lithium, lamotrigine, and quetiapine monotherapy, as well as olanzapine plus selective serotonin reuptake inhibitor (SSRI), and lithium or divalproex plus SSRI/bupropion remain first-line options. Lurasidone monotherapy and the combination of lurasidone or lamotrigine plus lithium or divalproex have been added as a second-line options. Ziprasidone alone or as adjunctive therapy, and adjunctive levetiracetam have been added as not-recommended options for the treatment of bipolar depression. Lithium, lamotrigine, valproate, olanzapine, quetiapine, aripiprazole, risperidone long-acting injection, and adjunctive ziprasidone continue to be first-line options for maintenance treatment of bipolar disorder. Asenapine alone or as adjunctive therapy have been added as third-line options. © 2012 John Wiley and Sons A/S.